Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials

Affiliations

¹ Department of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada. rpanacci@ucalgary.ca.
² Translational and Clinical Research Institute, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
³ New York University School of Medicine, New York, NY, USA.
⁴ Inflammation and Immunology, Pfizer Inc, Collegeville, PA, USA.
⁵ Inflammation and Immunology, Pfizer Inc, New York, NY, USA.
⁶ Inflammation and Immunology, Pfizer Inc, Groton, CT, USA.

Published Erratum

Remo Panaccione et al. Dig Dis Sci. 2021 Sep.

. 2021 Sep;66(9):3214-3215.

doi: 10.1007/s10620-020-06638-z.

¹ Department of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada. rpanacci@ucalgary.ca.
² Translational and Clinical Research Institute, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
³ New York University School of Medicine, New York, NY, USA.
⁴ Inflammation and Immunology, Pfizer Inc, Collegeville, PA, USA.
⁵ Inflammation and Immunology, Pfizer Inc, New York, NY, USA.
⁶ Inflammation and Immunology, Pfizer Inc, Groton, CT, USA.

No abstract available

Erratum for

Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Panaccione R, et al. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Dig Dis Sci. 2021. PMID: 32816215 Free PMC article. Clinical Trial.